Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure
The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2008 by Vanderbilt University.
Recruitment status was Active, not recruiting
Information provided by:
First received: September 19, 2005
Last updated: February 21, 2008
Last verified: February 2008
A study to determine the effect on renal function in renal transplant patients with biopsy proven CAN nephropathy who are switched from a CI triple drug regimen to a Rapamycin based triple drug regimen or maintained on their CI protocol
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
||Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure
Primary Outcome Measures:
- graft survival [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||December 2008 (Final data collection date for primary outcome measure)
Active Comparator: 1
pt will switch from calcineurin inhibitor (CYA, prgraf) to Rapamycin
Rapamycin will start within 24 hours of last calcineurin inhibitors (Cya, Prgraf). Initial dose of Rapamune 10mg will be given for 3 days and then dose will be adjusted to attain a target whole blood trough of 5-15
Other Name: Sirolimus
No Intervention: 2
Patient will remain on calcineruin inhibitor
|Ages Eligible for Study:
||12 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Patient is the recipient of a cadaveric or living donor renal transplant.
- Patient was > 12 years of age at the time of transplant.
- Patient is at least 3 months post-transplant.
- Patient has been on a calcineurin inhibitor based immunosuppression since the transplant.
Patient has one of the following risk factors for chronic renal allograft failure:
I. Serum creatinine > 2.0 mg/dL 3 months or later post-transplant in males patients.
II. Serum creatinine > 1.7 mg/dL 3 months or later post-transplant in female patients.
III. Serum > 30% increased over post discharge nadir.
- Patients had a renal biopsy that shows chronic allograft nephropathy.
- Patient or legal guardian had signed and dated an IRB approved informed consent document and is willing and able to follow study procedures.
If female and of child bearing potential, patient has a negative pregnancy test and agrees to practice effective birth control while receiving mycophenolate mofetil (MMF), Rapamycin and other immunosuppressants.
- Patient is the recipient of a solid organ transplant other than the kidney.
- Patient is dialysis dependent.
- Patient has recurrence of primary renal disease, or de novo renal disease.
- Patient has an estimated creatinine clearance <25ml/min calculated using the Crockcroft/Gault formula.
- Patient has changed maintenance immunosuppressant therapy (e.g., azathioprine to MMF) within three months of randomization.
- Baseline biopsy shows acute rejection Banff Grade > IIB.
- Patient required anti-lymphocyte therapy to treat rejection found on baseline biopsy.
- Patient has received an investigational immunosuppressant within three months.
- Patient is pregnant or lactating.
- Patient is a known carrier of any of the HIV viruses.
- Patient has known hypersensitivity to Rapamycin, or any of the excipients of the drug.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00223678
|Nashville, Tennessee, United States, 37232 |
||Anthony Langone, M.D.
No publications provided
||Dr Anthony Langone, Vanderbilt University
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 19, 2005
||February 21, 2008
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 23, 2014
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs